Trial Profile
A phase III long-term study to evaluate the safety and efficacy of TAC-202 in patients with chronic idiopathic urticaria and pruritus accompanied by skin diseases
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Bilastine (Primary)
- Indications Pruritus; Urticaria
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 13 Jan 2015 New trial record